Know Cancer

or
forgot password

PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis


Phase 3
18 Years
N/A
Not Enrolling
Both
Actinic Keratosis

Thank you

Trial Information

PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis


Actinic keratosis (AK) is a pre-cancerous skin abnormality usually caused by sun exposure.
Actinic keratoses occur most commonly in fair skin, especially in the elderly. They mainly
occur in sun-exposed skin areas like head and hands. It is standard of care to remove AK
when diagnosed, which can be achieved by either physical ablation, chemotherapeutic agents
or photodynamic therapy (PDT). A direct comparison versus placebo which is necessary for the
exact quantification of the effect of PD P 506 A has not yet been performed and is subject
of this study protocol.


Inclusion Criteria:



- Written informed consent

- Caucasian patients

- Diagnosis of actinic keratosis (AK) with at least three locally separated lesions
located on head and/or face (hairless areas)

- Selected AK study lesions have clearly defined margins and are mild to moderate

- The distance between the study lesion borders is > 1.0 cm

- Maximum diameter of each study lesion is 1.8 cm

- Skin sun sensitivity type I to IV according to Fitzpatrick

Exclusion Criteria:

- PDT Non-responder

- Pre-treatment of the AK lesions eligible for study procedures with pharmaceuticals
approved for the treatment of AK during the 4 weeks preceding PDT

- Pre-treatment of the AK lesions eligible for study procedures during the 2 weeks
preceding PDT with keratolytic agents e.g. TCA, urea or salicylic acid containing
formulations

- Pre-treatment with hypericin during the 2 weeks preceding PDT

- Treatment with systemic retinoids during the 3 months preceding PDT

- Treatment with cytostatics or radiation during the 3 months preceding PDT

- Female patients of childbearing potential

- Patients with clinically relevant suppression of the immune system

- Diagnosis of Porphyria

- Skin diseases that might interfere with response evaluation of study PDT

- Skin sun sensitivity type V or VI according to Fitzpatrick

- Known intolerance to one or more of the ingredients of the study medication

- Dementia or psychic condition that might interfere with the ability to understand the
study and thus give a written informed consent

- Simultaneous participation in another clinical study or participation in another
clinical study in the 30 days directly preceding inclusion

- Suspected lack of compliance

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Complete clinical clearance rate (CCR) of treated actinic keratosis lesions 12 weeks after PDT

Outcome Time Frame:

12 weeks

Principal Investigator

Axel Hauschild, Professor MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Christian-Albrechts-Universit├Ąt zu Kiel, Germany

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

AK 03

NCT ID:

NCT00308854

Start Date:

March 2006

Completion Date:

December 2007

Related Keywords:

  • Actinic Keratosis
  • AK
  • PDT
  • Keratosis
  • Keratosis, Actinic

Name

Location